A randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of an oral formulation of TUR-004 in healthy adult subjects

Trial Profile

A randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of an oral formulation of TUR-004 in healthy adult subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2015

At a glance

  • Drugs TUR 004 (Primary)
  • Indications Generalised seizures
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Nov 2015 According to a Turing Pharmaceuticals media release, dosing of the first group of subjects has been initiated.
    • 16 Nov 2015 Status changed from not yet recruiting to recruiting, as reported in a Turing Pharmaceuticals media release.
    • 12 Nov 2015 According to a Turing Pharmaceuticals media release, FDA granted Fast Tack Designation to TUR-004.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top